Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

Adaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to unlock shareholder value. The MRD segment has shown strong growth, increasing revenue from $103 million in 2023 to $212 million in 2025, while the Immune Medicine segment has advanced in drug discovery capabilities. The company expects to finalize its separation strategy by end of 2026. ADPT shares rose 0.74% to $17.59, with analysts maintaining a Buy rating and average price target of $20.20.